Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in

Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2–Exposed CoronaVac- Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study in: The American Journal of Tropical

Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

Frontiers Immunogenicity, Effectiveness, and Safety of Inactivated Virus ( CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

Effectiveness of CoronaVac vaccination against COVID-19 development in healthcare workers: real-life data

Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2–Exposed CoronaVac- Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study in: The American Journal of Tropical

Effectiveness of CoronaVac, AZD1222, and BNT162b2 vaccine boosters

Vaccines, Free Full-Text

Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis, BMC Medicine

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study